logo-loader
ImmuPharma PLC

Successful AstraZeneca lupus study bodes well for ImmuPharma's Lupuzor - analyst

Dr Navid Malik, Head of Life Sciences Research, tells Proactive London's Andrew Scott the recent positive update for AstraZeneca's lupus drug Anifrolumab is not only positive for the Lupus field but also serves as a reminder that ImmuPharma PLC’s (LON:IMM) Lupuzor drug could represent a highly successful product.

AstraZeneca announced positive topline data from its second Phase III clinical trial in Lupus patients, comparing Anifrolumab to the current standard of care.

Quick facts: ImmuPharma PLC

Price: 7.8609 GBX

Market: AIM
Market Cap: £13.16 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Immupharma chairman details £2.66mln financing and open label extension study

ImmuPharma PLC’s (LON:IMM) chairman Tim McCarthy caught up with Proactive London's Andrew Scott to discuss the results of a follow-up study which was designed to evaluate Lupuzor’s safety and tolerability. McCarthy says the six month extension study confirmed its outstanding and robust...

on 4/7/19

2 min read